Amphastar Pharmaceuticals, Inc. (AMPH)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 70M 140M 210M Q3 '21: 112.2M Q4 '21: 120.9M Q1 '22: 120.4M Q2 '22: 123.5M Q3 '22: 120.1M Q4 '22: 135M Q1 '23: 140M Q2 '23: 145.7M Q3 '23: 180.6M Q4 '23: 178.1M Q1 '24: 171.8M Q2 '24: 182.4M Q3 '24: 191.2M Q4 '24: 186.5M Q1 '25: 170.5M Q2 '25: 174.4M Q3 '25: 191.8M Q4 '25: 183.1M Q1 '26: 171.2M Q2 '26: 183.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 40M 80M 120M Q3 '21: 51.2M Q4 '21: 56.2M Q1 '22: 55.8M Q2 '22: 63.4M Q3 '22: 58.5M Q4 '22: 71.2M Q1 '23: 73.8M Q2 '23: 72.7M Q3 '23: 108.4M Q4 '23: 96.1M Q1 '24: 90.1M Q2 '24: 95.2M Q3 '24: 101.9M Q4 '24: 86.6M Q1 '25: 85.3M Q2 '25: 86.5M Q3 '25: 98.6M Q4 '25: 85.7M Q1 '26: 70.3M Q2 '26: 93.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Income Quarterly

0 25M 50M 75M Q3 '21: 24.8M Q4 '21: 24.3M Q1 '22: 21.6M Q2 '22: 24.8M Q3 '22: 23.2M Q4 '22: 37.8M Q1 '23: 33.4M Q2 '23: 36.9M Q3 '23: 72.7M Q4 '23: 54M Q1 '24: 48M Q2 '24: 55.2M Q3 '24: 57M Q4 '24: 45.1M Q1 '25: 37.3M Q2 '25: 42.2M Q3 '25: 25.3M Q4 '25: 35.6M Q1 '26: 13.6M Q2 '26: 39.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

0 20M 40M 60M Q3 '21: 29.5M Q4 '21: 19.8M Q1 '22: 24.3M Q2 '22: 17.3M Q3 '22: 15.9M Q4 '22: 33.9M Q1 '23: 26M Q2 '23: 26.1M Q3 '23: 49.2M Q4 '23: 36.2M Q1 '24: 43.2M Q2 '24: 37.9M Q3 '24: 40.4M Q4 '24: 38M Q1 '25: 25.3M Q2 '25: 31M Q3 '25: 17.4M Q4 '25: 24.4M Q1 '26: 6.4M Q2 '26: 30.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 35M 70M 105M Q3 '21: 61M Q4 '21: 64.7M Q1 '22: 64.5M Q2 '22: 60.1M Q3 '22: 61.6M Q4 '22: 63.9M Q1 '23: 66.2M Q2 '23: 73M Q3 '23: 72.2M Q4 '23: 82M Q1 '24: 81.7M Q2 '24: 87.2M Q3 '24: 89.3M Q4 '24: 99.9M Q1 '25: 85.3M Q2 '25: 87.9M Q3 '25: 93.2M Q4 '25: 97.4M Q1 '26: 100.8M Q2 '26: 90.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

0 25M 50M 75M Q3 '21: 2.6M Q4 '21: 40.4M Q1 '22: 50.8M Q2 '22: 2.8M Q3 '22: 20.4M Q4 '22: 15.2M Q1 '23: 40.4M Q2 '23: 54.9M Q3 '23: 64.3M Q4 '23: 23.9M Q1 '24: 55.3M Q2 '24: 69.1M Q3 '24: 60M Q4 '24: 29M Q1 '25: 35.1M Q2 '25: 35.6M Q3 '25: 52.6M Q4 '25: 32.9M Q1 '26: 47.8M Q2 '26: 51.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-25M 0 25M 50M 75M Q3 '21: -4.7M Q4 '21: 33.6M Q1 '22: 44.6M Q2 '22: -3.1M Q3 '22: 14.8M Q4 '22: 8.9M Q1 '23: 30.9M Q2 '23: 45.9M Q3 '23: 54.1M Q4 '23: 14.4M Q1 '24: 46.5M Q2 '24: 63.1M Q3 '24: 46.2M Q4 '24: 16.6M Q1 '25: 24.4M Q2 '25: 25M Q3 '25: 47.2M Q4 '25: 24.6M Q1 '26: 38.3M Q2 '26: 42.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 20M 40M 60M Q1 '20: 48.2M Q2 '20: 46.8M Q3 '20: 49.8M Q1 '21: 49.5M Q2 '21: 49.6M Q3 '21: 50M Q1 '22: 52M Q2 '22: 53.2M Q3 '22: 52.8M Q1 '23: 52M Q2 '23: 53.1M Q3 '23: 53.9M Q1 '24: 53M Q2 '24: 52M Q3 '24: 51.9M Q1 '25: 49.9M Q2 '25: 48.1M Q3 '25: 47.7M Q1 '26: 46.5M Q2 '26: 44.2M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

0.00 1.50 3.00 4.50 Q3 '21: 0.72 Q4 '21: 1.25 Q1 '22: 1.62 Q2 '22: 1.79 Q3 '22: 1.50 Q4 '22: 1.75 Q1 '23: 1.78 Q2 '23: 1.94 Q3 '23: 2.55 Q4 '23: 2.59 Q1 '24: 2.90 Q2 '24: 3.14 Q3 '24: 3.01 Q4 '24: 3.06 Q1 '25: 2.76 Q2 '25: 2.67 Q3 '25: 2.26 Q4 '25: 2.03 Q1 '26: 1.66 Q2 '26: 1.69 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.